以β1整合素结合的适配体靶向三阴性乳腺癌细胞。
Targeting triple-negative breast cancer cells with a β1-integrin binding aptamer.
发表日期：2023 Sep 12
作者：
Karlis Pleiko, Maarja Haugas, Vadims Parfejevs, Teodors Pantelejevs, Emilio Parisini, Tambet Teesalu, Una Riekstina
来源：
BIOMEDICINE & PHARMACOTHERAPY
摘要：
靶向治疗方案已经增加了三阴性乳腺癌患者的治疗选择。然而，由于可靶标生物标志物的匮乏和肿瘤的异质性，精准引导干预手段的潜力受到了限制。作为亲和靶向配体，适配体对目标分子具有较高的选择性。相较于抗体，适配体具有较低的分子量，在运输过程中具有更高的稳定性，免疫原性降低，以及更高的组织摄取能力。最近，我们报道了发现了GreenB1适配体，该适配体在培养的三阴性乳腺癌细胞MDA-MB-231内部化。我们显示GreenB1适配体特异性靶向β1整合素，这是之前与乳腺癌细胞侵袭和迁移相关联的蛋白质。适配体以低纳摩尔亲和力结合到β1整合素上。我们的发现表明GreenB1引导的精确药剂可能适用于过表达β1整合素的肿瘤的诊断和治疗。© 2023 作者。
Targeted therapies have increased the treatment options for triple-negative breast cancer patients. However, the paucity of targetable biomarkers and tumor heterogeneity have limited the ability of precision-guided interventions to live up to their full potential. As affinity-targeting ligands, aptamers show high selectivity toward target molecules. Compared with antibodies, aptamers have lower molecular weight, increased stability during transportation, reduced immunogenicity, and increased tissue uptake. Recently, we reported discovery of the GreenB1 aptamer, which is internalized in cultured triple-negative MDA-MB-231 human breast cancer cells. We show that the GreenB1 aptamer specifically targets β1-integrin, a protein linked previously to breast cancer cell invasiveness and migration. Aptamer binds to β1-integrin with low nanomolar affinity. Our findings suggest potential applications for GreenB1-guided precision agents for diagnosis and therapy of cancers overexpressing β1-integrin.© 2023 The Author(s).